8-K: Forte Biosciences Reports Positive Phase 1b Celiac Disease Trial Results for FB102, Advancing to Phase 2

Forte Biosciences announced positive Phase 1b clinical trial data for its lead program FB102 in celiac disease, paving the way for a Phase 2 study initiation.

Summary

• Forte Biosciences announced positive data from its Phase 1b trial (FB102-101) for lead program FB102 in celiac disease.
• The study enrolled 32 subjects (24 on FB102, 8 on placebo) who received 4 doses of FB102 (10 mg/kg) and underwent a 16-day gluten challenge.
• FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (p=0.0099), with a mean change from baseline of 0.079 for FB102 treated subjects compared to -1.849 for placebo subjects.
• A statistically significant difference was observed in the change in CD3-positive T cells (IELs) density, with a decline of 1.5 for FB102 treated subjects compared to an increase of 13.3 for placebo subjects (p=0.0035).
• The mean change in the Villus height to Crypt depth (Vh:Cd) ratio from baseline showed a 73% improvement for FB102 (-0.046) compared to placebo (-0.173).
• Gluten challenge-induced GI symptoms (nausea, vomiting, diarrhea, abdominal pain, abdominal bloating) demonstrated a 42% benefit for FB102 treated subjects (4.0 events per subject) compared to placebo (6.9 events per subject).
• FB102 was generally safe and well-tolerated, with primarily mild (grade 1) treatment-emergent adverse events (TEAEs) and no grade 3 or higher SAEs reported in the FB102 arm.
• The company plans to initiate a Phase 2 celiac disease study with topline readout expected in 2026.
• Topline results for the FB102 vitiligo study are expected in the first half of 2026.

Sentiment

Score: 8

Explanation: The document reports strong positive clinical trial results for a lead candidate in a disease with no approved therapies, indicating significant progress and potential. The safety profile is also favorable. While future capital needs are mentioned as a risk, this is common for clinical-stage biotechs.

Positives

• FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (p=0.0099).
• FB102 showed a statistically significant difference in the change in CD3-positive T cells (IELs) density (p=0.0035).
• A 73% improvement in the Villus height to Crypt depth (Vh:Cd) ratio was observed for FB102 compared to placebo.
• FB102 demonstrated a 42% benefit in reducing gluten challenge-induced GI symptoms compared to placebo.
• The study had no dropouts, indicating good tolerability and patient retention.
• FB102 was generally safe and well-tolerated, with treatment-emergent adverse events being primarily mild (grade 1) and no grade 3 or higher SAEs reported in the FB102 arm.
• The positive results in celiac disease are encouraging for the biology of additional FB102 indications, including vitiligo, alopecia areata, and type 1 diabetes.

Risks

• Risks related to Forte's ability to obtain sufficient additional capital to continue to advance its product candidate, FB102.
• Uncertainties associated with the clinical development and regulatory approval of FB102, including potential delays in the commencement, enrollment, and completion of clinical trials.
• The risk that results from preclinical and Phase 1b trials may not be predictive of future results from later-stage clinical trials.
• Risks associated with the failure to realize any value from FB102 in light of inherent risks, expense, and difficulties involved in successfully bringing product candidates to market.
• The impact of government laws and regulations on the company's operations and product development.
• Forte's ability to protect its intellectual property position.
• Forte's estimates regarding future revenue, expenses, capital requirements, and need for additional financing.
• The impact of global events on the company, the company's industry, or the economy generally.

Future Outlook

Forte Biosciences plans to initiate a Phase 2 celiac disease study in the second half of 2025, with topline data expected in 2026. They also anticipate topline results from the FB102 vitiligo study in the first half of 2026. The company is evaluating study design and initiation for Phase 2 in Alopecia Areata and plans initiation for Type 1 Diabetes in 2026, highlighting FB102's potential across multiple autoimmune indications.

Management Comments

• "We want to congratulate all of the investigators and researchers that supported this study. I also want to acknowledge the incredible dedication and hard work of the Forte team." Paul Wagner, Ph.D., CEO and Chairperson of Forte Biosciences.
• "Celiac disease is debilitating for many patients with even trace exposure to gluten. FB102 has taken a big step forward towards addressing this very large unmet need with the results from this study." Paul Wagner, Ph.D., CEO and Chairperson of Forte Biosciences.
• "The Phase 2 celiac disease study is initiating with a topline readout expected in 2026." Paul Wagner, Ph.D., CEO and Chairperson of Forte Biosciences.
• "These results are also very encouraging given the biology of the additional FB102 indications including vitiligo, alopecia areata and type 1 diabetes." Paul Wagner, Ph.D., CEO and Chairperson of Forte Biosciences.
• "We also look forward to reading out the topline results of the FB102 vitiligo study in the first half of 2026." Paul Wagner, Ph.D., CEO and Chairperson of Forte Biosciences.

Industry Context

Celiac disease currently has no approved therapies, representing a significant unmet medical need for an estimated 2.5 million people in the US, with 0.3% to 0.5% being non-responsive to a gluten-free diet. FB102's mechanism, targeting both IL-2 and IL-15, offers a potential advantage over other investigational drugs that often target a single cytokine. The positive Phase 1b data positions FB102 as a promising candidate in this underserved market. The company also highlights the "pipeline-in-a-product" potential of FB102 for other autoimmune diseases like vitiligo, alopecia areata, and type 1 diabetes, where current treatments (e.g., JAK inhibitors) face regulatory scrutiny and safety concerns, suggesting a need for safer alternatives.

Comparison to Industry Standards

• Celiac Disease: There are no approved treatment options for celiac disease, positioning FB102 to address a significant unmet need. FB102's dual IL-2/IL-15 blocking mechanism is presented as a potential advantage over other investigational drugs that often have single-targeting mechanisms (e.g., IMGX-003, CNP-101/TAK-101, IMU-856, CALY-002, TMP502, TAK-062, Ordesekimab, EQ-102, KAN-101, E40, TEV-53408, TAK227/ZED1227, DONQ52, amlitelimab).
• Vitiligo: While JAK inhibitors (e.g., ritlecitinib (LITFULO), Tofacitinib (ZELJANZ), Upadacitinib, povorcitinib (Incyte INCB54707)) have shown efficacy, Forte notes regulatory scrutiny and black box warnings for this class. FB102's unique mechanism of inhibiting two cytokines (IL-2/IL-15) is presented as a potentially safer alternative to single-cytokine or JAK-based therapies.
• Alopecia Areata: Similar to vitiligo, JAK inhibitors (e.g., ritlecitinib (LITFULO), baricitinib (Olumiant), deuruxolitinib (LEQSELVI), Upadacitinib) are noted for efficacy but also for black box warnings. FB102's anti-CD122 mechanism is presented as a potential safer alternative to these and other single-target therapies (e.g., etrasimod (VELSIPITY), IMG-007, dupilumab (Dupixent), Rezpegaldesleukin, bempikibart, EQ101).
• Type 1 Diabetes: Two approved products, LANTIDRA and TZIELD, carry significant safety challenges. LANTIDRA requires hospitalization, costs $300K/cycle, and has 90% serious AEs. TZIELD is an IV infusion, costs $190K/cycle, and has severe AEs including lymphopenia. FB102 is presented as a potentially safer way to delay onset, with a unique MOA directly impacting T-cells, unlike most other drug candidates that use indirect pathways.

Stakeholder Impact

• Shareholders: Positive clinical data could lead to increased investor confidence and potential share price appreciation. Future capital raises could dilute existing shares.
• Patients (Celiac Disease): The positive Phase 1b results offer hope for a much-needed therapeutic option for a debilitating autoimmune condition with no approved treatments.
• Patients (Vitiligo, Alopecia Areata, Type 1 Diabetes): The encouraging results in celiac disease, given the shared biology, suggest potential for FB102 in these other autoimmune conditions, offering hope for new, potentially safer treatments.
• Employees: Continued positive clinical development supports job security and potential growth opportunities within the company.

Next Steps

• Initiation of Phase 2 celiac disease study in 2H 2025.
• Expected US IND for celiac disease Phase 2 in late 2025/early 2026.
• Topline data readout for Phase 2 celiac disease study expected in 2026.
• Topline results for FB102 vitiligo study expected in 1H 2026.
• Evaluating study design and initiation for Alopecia Areata Phase 2.
• Initiation of Type 1 Diabetes Phase 2 in 2026.

Key Dates

Recommendation

Keywords

Forte Biosciences, FBRX, FB102, Celiac Disease, Phase 1b, Clinical Trial, Autoimmune Disease, Biopharmaceutical, Drug Development, VCIEL, IEL, Villus Height, Gluten Challenge, Vitiligo, Alopecia Areata, Type 1 Diabetes, CD122, IL-2, IL-15